We empower people with innovative treatment solutions

 

News & Insights

SEPTEMBER 12, 2024
Opioid misuse and overdose in the aging population needs increased attention

SEPTEMBER 3, 2024
Orexo to attend the Pareto Securities 15th Annual Healthcare Conference on Sep. 19

JULY 17, 2024
Orexo Q2 2024 Interim Report

 

 

A commercial stage pharmaceutical company with three revenue generating pharmaceutical products

 


AmorphOX® - a world-class powder-based drug delivery technology, leading to a new wave of a both small and large molecule pharmaceuticals.

 

 

Development pipeline targeting large medical needs

ESG sustainable investing

Read all documents related to the refinancing of the existing bond - MARCH 2024

Read more

Key financial figures

Group net revenue

615 MSEK
Last Twelve Months, Q323-Q224

Group EBITDA

22 MSEK
Last Twelve Months, Q323-Q224

US Commercial segment EBIT

145 MSEK
Last Twelve Months, Q323-Q224

Cash position

140 MSEK
Q224
To read all NEWS go to Media in the top menu